Capsida Biotherapeutics to Showcase Advancements in Gene Therapy
![Capsida Biotherapeutics to Showcase Advancements in Gene Therapy](https://investorshangout.com/images/blog/ihnews-Capsida%20Biotherapeutics%20to%20Showcase%20Advancements%20in%20Gene%20Therapy.jpg)
Capsida Biotherapeutics to Showcase its Innovative Programs
Capsida Biotherapeutics, a leader in targeted gene therapy, is gearing up to present at several upcoming investor and industry conferences. These events will shed light on the significant advancements made within its wholly owned programs, particularly those targeting **genetic epilepsy** due to STXBP1 mutations and **Parkinson's disease** caused by GBA mutations. Both programs are set to enter the clinic by the first half of 2025, marking a pivotal moment for the company and its commitment to addressing pressing medical challenges.
Upcoming Conferences and Presentations
The company's management team is excited to highlight its progress at notable conferences scheduled in the near future:
Morgan Stanley Healthcare Conference
This prestigious conference will take place in early September. Capsida is set to deliver a corporate presentation on Thursday, September 5, 2024, at **4:05 PM ET**. This event presents an opportunity for the firm to connect with key stakeholders in the healthcare sector.
Mass General Brigham World Medical Innovation Forum
Later in September, Capsida will participate in a panel discussion focused on the future of viral vector manufacturing and the delivery of genetic medicines. This session is part of the **Mass General Brigham World Medical Innovation Forum** from September 23-25, 2024, with Capsida’s participation on **Monday, September 23rd** at **4:05 PM ET**.
Bank of America Healthcare Trailblazers Conference
On September 25, 2024, Capsida will engage in one-on-one investor meetings at the Bank of America Healthcare Trailblazers Conference. This setting provides a unique avenue for in-depth discussions regarding the company’s innovative strategies and future outlook. The venue for the event will also be located in Boston.
Chardan's Annual Genetic Medicines Conference
Capping off the month, Capsida will feature not only a corporate presentation but also participate in various panels at Chardan's **8th Annual Genetic Medicines Conference** from September 30 to October 1, 2024. Notably, a significant panel titled 'Engineering of AAVs: The Promise of Next Gen AAVs' is scheduled for **Monday, September 30**, with key discussions beginning at **9:30 AM ET**.
Cell & Gene Meeting on the Mesa
In early October, Capsida will conclude its conference participation at the **Cell & Gene Meeting on the Mesa**, slated for October 7-9, 2024. The corporate presentation is set for **October 8**, and attendees can expect insightful discussions centered around Capsida’s pioneering approaches in gene therapy.
About Capsida Biotherapeutics
Capsida Biotherapeutics is a fully integrated gene therapy company employing innovative strategies to develop disease-modifying treatments for both rare and more common diseases afflicting individuals of all ages. The firm’s intravenously administered gene therapies leverage proprietary engineered capsids, optimizing the delivery of therapeutic agents while minimizing effects on non-target organs such as the liver. Currently, the company boasts three wholly owned programs aimed at providing best-in-class treatments for the aforementioned genetic conditions, all within the framework of IND-enabling studies and poised for clinical entry in the foreseeable future.
Moreover, Capsida retains collaborative ventures with major partners like AbbVie and Lilly, enhancing its capacity for advancement within the central nervous system therapeutics domain. Established in 2019 with visionary investment from Versant Ventures and Westlake Village BioPartners, the company has its roots in trailblazing research conducted under the guidance of Dr. Viviana Gradinaru at Caltech.
Frequently Asked Questions
What is the focus of Capsida Biotherapeutics?
Capsida Biotherapeutics specializes in targeted gene therapy for various diseases, notably genetic epilepsy and Parkinson's disease.
When are the upcoming conferences where Capsida will present?
Capsida will present at several upcoming conferences including the Morgan Stanley Healthcare Conference in early September and the Cell & Gene Meeting on the Mesa in October.
What are the key presentations Capsida will make?
Capsida will highlight its IV-administered programs CAP-002 and CAP-003, which are targeting genetic epilepsy and Parkinson’s disease respectively.
Who are Capsida’s strategic partners?
Capsida has established validating partnerships with prominent companies such as AbbVie, Lilly, and CRISPR Therapeutics.
When is Capsida's corporate presentation available for viewing?
The Capsida corporate presentation can be accessed on the company's website under the News section.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- GlobalVetLink's Automation Tool Enhances Rabies Vaccine Management
- CIBC Mellon, UPP & IMCO to Host Investment Fund Conference
- Ilegal Mezcal Launches Unique Reposado Caribbean Cask Finish
- Hackensack Meridian Health Foundation Gala Honors Eli Manning
- UK Investor Behavior: Shift from Stocks to Money Markets
- Apple's Anticipated 'Glowtime' Event to Unveil Innovations
- Dollar Tree's Earnings Drop and Future Outlook Challenges
- Rising Bankruptcy Filings in Commercial Sector Highlight Trends
- Metabolomics Technologies Market Set to Surge by 2034
- Myosin's Innovative Marketing Platform Redefines Advertising Impact
- Acer Introduces Eco-Friendly Vero PD2 Series LED Projectors
- Tower Arch Capital Partners with ACS Manufacturing for Growth
- Winking Studios Unveils GenMotion.AI for 3D Animation Innovation
- Bybit Web3 Launches Babylon Season with Exciting Opportunities
- Wells Fargo Advises Investors to Buy Election Weakness
- Tech Stocks Struggle Amid Economic Growth Concerns
- Blue Circle Health Launches New T1D Program in Northern States
- West Shore Home Appoints Al Patel as New Chief Marketing Officer
- Digestion Resistant Maltodextrin Market Set for Remarkable Growth
- Mid-Atlantic BioTherapeutics and Accelero Unite for Drug Discovery
- Peptide Therapeutics Market to Reach USD 85.9 Billion by 2031
- Saphyre and WTax Launch Innovative Tax Reclaim Solutions
- Sumeet Chabria Joins Genesis as Senior Advisor for Growth
- Steve Varsano Receives Aviator Award for Lifetime Achievement
- Volaris Announces August 2024 Traffic Outcomes: 87% Load Factor
Recent Articles
- GlobalVetLink's Automation Tool Enhances Rabies Vaccine Management
- Acer Introduces Eco-Friendly Vero PD2 Series LED Projectors
- Digestion Resistant Maltodextrin Market Set for Remarkable Growth
- Leukemia Treatment Drugs Market Projected to Reach $46.1 Billion
- KommuneKredit Reports Significant Growth in 2024 Financials
- Hilb Group Expands with Strategic Acquisition in Benefits Sector
- Cineverse Expands Data Security with LiveRamp Integration
- Projected Growth of Global Cosmetics Market to USD 764.35 Billion
- NKF Launches Essential Online Education for Kidney Disease
- Acer Unveils TravelMate P6 14 AI: A Game Changer in Laptops
- GridGain to Showcase Real-Time Data Innovations at Conferences
- Aurigo Software Enhances Right of Way Solutions for Agencies
- Wearable Devices Innovates Gesture Control with Neural Tech
- Summit Ridge Energy Partners with Siemens for Domestic Inverters
- Fossil Group Welcomes Franco Fogliato as New CEO
- Retail Ready Packaging Market Reaches US$ 102.2 Billion by 2032
- CloudCasa by Catalogic Boosts Multi-Cloud Services and Support
- Exploring the Promising CD47 Inhibitor Drug Market Growth
- Fed's New Strategy Sparks Concerns Among Investors
- RCap Equity Partners Invests in Northeast Contracting Corp.
- Axsome Therapeutics' NDA Resubmission for AXS-07 Accepted by FDA
- Vertex Completes Acquisition of ecosio for Enhanced Solutions
- Huawei Innovates Wildfire Detection Solution to Save Lives
- Automotive 3D Map System Market to Reach $12.8 Billion by 2032
- Strategic Portfolio Rebalancing Ahead of Fed’s Rate Cuts